All In Biotech

Free tool

FAERS Monitor: Atmeksi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219843 or its brand name (Atmeksi, Methocarbamol). Reports on generic versions are filed under their own applications.

Reports

17,199

Serious

10,693

62% of reports

Hospitalization

5,205

Death reported

1,418

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue1,273
  • pain1,245
  • nausea1,191
  • drug ineffective1,140
  • headache973
  • diarrhoea882
  • off label use837
  • fall813
  • dyspnoea788
  • arthralgia766
  • dizziness696
  • back pain652
  • chronic kidney disease648
  • anxiety642
  • vomiting623

Reports by year received

View as table
YearReports
2004108
2005134
2006131
200784
2008134
2009176
2010199
2011253
2012349
2013346
2014378
2015695
2016972
2017845
20181,084
20191,240
20201,353
20211,120
20221,214
20231,273
20241,485
20251,975
20261,651

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,036,960 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic kidney diseaseSignal64810.59.75,540
back painSignal6523.43.21,135
fallSignal8133.02.81,091
anxietySignal6422.82.6729
painSignal1,2452.52.41,131
arthralgiaSignal7662.32.1544
fatigueSignal1,2732.01.9660
headache9731.91.8425
nausea1,1911.81.7474
dizziness6961.71.6208
dyspnoea7881.71.6234
diarrhoea8821.71.6245
vomiting6231.61.5151
off label use8371.21.121
drug ineffective1,1401.11.04

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.